ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, Nielsen, H & Thisted, R K 2022, ' Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO) : a randomised controlled trial ', The Lancet. Infectious diseases, vol. 22, no. 5, pp. 622-635 . https://doi.org/10.1016/S1473-3099(21)00751-9 ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, Johansen, I S & Larsen, L 2022, ' Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO) : a randomised controlled trial ', The Lancet Infectious Diseases, vol. 22, no. 5, pp. 622-635 . https://doi.org/10.1016/S1473-3099(21)00751-9 The Lancet. Infectious Diseases
Italian PBC Study Group and the UK–PBC Consortium 2018, ' Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis : development and validation of the UDCA Response Score ', The Lancet Gastroenterology and Hepatology, vol. 3, no. 9, pp. 626-634 . https://doi.org/10.1016/S2468-1253(18)30163-8